Vaccination against tumour blood vessels in colorectal cancer

European Journal of Surgical Oncology

Volumn 40, Issue 2, 2014, Pages 133-136

  Ferguson, H J M ^a,b   Wragg, J ^a   Ismail, T ^b   Bicknell, R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CANCER VACCINES; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM MICROMETASTASIS; VACCINES, CONJUGATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84895069468     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2013.11.025     Document Type: Article

References (41)

1. C.E. Dukes, and H.J. Bussey The spread of rectal cancer and its effect on prognosis Br J Cancer 12 3 1958 Sep 309 320
2. A. Jemal, R. Siegel, and E. Ward et al. Cancer statistics, 2006 CA Cancer J Clin 56 2 2006 Mar 106 130
3. P. Quirke, P. Durdey, M.F. Dixon, and N.S. Williams Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision Lancet 2 8514 1986 Nov 1 996 999
4. N.C. Tebbutt, E. Cattell, R. Midgley, D. Cunningham, and D. Kerr Systemic treatment of colorectal cancer Eur J Cancer 38 7 2002 May 1000 1015
5. J. Lokich Infusional 5-FU: historical evolution, rationale, and clinical experience Oncology (Williston Park, N.Y 12 10 Suppl. 7 1998 Oct 19 22
6. H. Kelly, and R.M. Goldberg Systemic therapy for metastatic colorectal cancer: current options, current evidence J Clin Oncol 23 20 2005 Jul 10 4553 4560
7. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 21 1971 Nov 18 1182 1186
8. J. Folkman, P. Cole, and S. Zimmerman Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment Ann Surg 164 3 1966 Sep 491 502
9. D.W. Siemann The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents Cancer Treat Rev 37 1 2011 Feb 63 74
10. D.W. Siemann, and M.R. Horsman Vascular targeted therapies in oncology Cell Tissue Res 335 1 2009 Jan 241 248
11. W.S. Kamoun, S.-S. Chae, and D.A. Lacorre et al. Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks Nat Methods 7 8 2010 Aug 655 660
12. R.K. Jain Transport of molecules in the tumor interstitium: a review Cancer Res 47 12 1987 Jun 15 3039 3051
13. A. Hajitou, R. Pasqualini, and W. Arap Vascular targeting: recent advances and therapeutic perspectives Trends Cardiovasc Med 16 3 2006 Apr 80 88
14. S. Moncada The vascular endothelium 2006
15. K. Red-Horse, Y. Crawford, F. Shojaei, and N. Ferrara Endothelium-microenvironment interactions in the developing embryo and in the adult Dev Cell 12 2 2007 Feb 181 194
16. L.L. Nikitenko Vascular endothelium in cancer Cell Tissue Res 335 1 2009 Jan 223 240
17. B. St Croix, C. Rago, and V. Velculescu et al. Genes expressed in human tumor endothelium Science 289 5482 2000 Aug 18 1197 1202
18. T. Boehm, J. Folkman, T. Browder, and M.S. O'Reilly Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature 390 6658 1997 Nov 27 404 407
19. F.J. Burrows, and P.E. Thorpe Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature Proc Natl Acad Sci U S A 90 19 1993 Oct 1 8996 9000
20. R.A. Brekken, J.P. Overholser, V.A. Stastny, J. Waltenberger, J.D. Minna, and P.E. Thorpe Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice Cancer Res 60 18 2000 Sep 15 5117 5124
21. J. Welti, S. Loges, S. Dimmeler, and P. Carmeliet Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer J Clin Invest 123 8 2013 Aug 1 3190 3200
22. M.G. Hanna, H.C. Hoover, J.B. Vermorken, J.E. Harris, and H.M. Pinedo Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise Vaccine 19 17-19 2001 Mar 21 2576 2582
23. J.R. van Beijnum, R.P. Dings, and E. van der Linden et al. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature Blood 108 7 2006 Oct 1 2339 2348
24. P. Oh, Y. Li, and J. Yu et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy Nature 429 6992 2004 Jun 10 629 635
25. R.A. Reisfeld, A.G. Niethammer, Y. Luo, and R. Xiang DNA vaccines suppress tumor growth and metastases by the induction of anti-angiogenesis Immunol Rev 199 2004 Jun 181 190
26. Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. clincancerres.aacrjournals.org.
27. Y. Li, M.-N. Wang, and H. Li et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis J Exp Med 195 12 2002 Jun 17 1575 1584
28. N. Matsushita, A. Aruga, Y. Inoue, Y. Kotera, K. Takeda, and M. Yamamoto Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer Oncol Rep 29 3 2013 Mar 951 959
29. S. Mosolits, G. Ullenhag, and H. Mellstedt Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results Ann Oncol 16 6 2005 Jun 847 862
30. D. Nagorsen, and E. Thiel Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer Clin Cancer Res 12 10 2006 May 15 3064 3069
31. R.J. Cersosimo Management of advanced colorectal cancer, part 2 Am J Health Syst Pharm 70 6 2013 Mar 15 491 506
32. L.B. Saltz, S. Clarke, and E. Díaz-Rubio et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 12 2008 Apr 20 2013 2019
33. O. Casanovas, R. Hickey, G. Bergers, and D. Hanahan Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 4 2005 Oct 299 309
34. A. Bagri, L. Berry, and B. Gunter et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy Clin Cancer Res 16 15 2010 Aug 1 3887 3900
35. R. Xiang, Y. Luo, A.G. Niethammer, and R.A. Reisfeld Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis Immunol Rev 222 2008 Apr 117 128
36. C.D. Kaplan, J.A. Krüger, H. Zhou, Y. Luo, R. Xiang, and R.A. Reisfeld A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma Vaccine 24 47-48 2006 Nov 17 6994 7002
37. Y. Okaji, N.H. Tsuno, and J. Kitayama et al. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity Cancer Sci 95 1 2004 Jan 85 90
38. J.B. Vermorken, A.M. Claessen, and H. van Tinteren et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial Lancet 353 9150 1999 Jan 30 345 350
39. Y. Okaji, N.H. Tsuno, and M. Tanaka et al. Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy Eur J Cancer 44 3 2008 Feb 383 390
40. L. Huminiecki, M. Gorn, S. Suchting, R. Poulsom, and R. Bicknell Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis Genomics 79 4 2002 Apr 547 552
41. M. Mura, R.K. Swain, and X. Zhuang et al. Identification and angiogenic role of the novel tumor endothelial marker CLEC14A Oncogene 31 3 2012 Jan 19 293 305